natgillin/translations-raw huggingface dataset:
Common (may affect up to 1 in 10 people): Influenza (flu); blocked nose, sore throat and discomfort when swallowing; headache; swelling of arms, hands, legs, ankles or feet; tiredness; asthenia (weakness); redness and warm feeling of the face and/or neck. 
Pogosti (pojavijo se pri do 1 od 10 ljudi): influenca (gripa); zamašen nos, vneto žrelo in težave pri požiranju; glavobol; otekanje rok, dlani, nog, gležnjev ali stopal; utrujenost; astenija (šibkost); pordelost in občutek toplote na obrazu in/ali vratu.
% of patients who experienced peripheral oedema 
% bolnikov s perifernimi edemi valsartan (mg)
Dafiro 5 mg/80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone. 
Zdravilo Dafiro 5 mg/80 mg lahko uporabite pri bolnikih, pri katerih krvni tlak ni ustrezno urejen samo s 5 mg amlodipina ali z 80 mg valsartana.
Dafiro 10 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Dafiro 5 mg/160 mg. 
Zdravilo Dafiro 10 mg/160 mg lahko uporabite pri bolnikih, pri katerih krvni tlak ni ustrezno urejen samo z 10 mg amlodipina ali s 160 mg valsartana ali s kombinacijo zdravila Dafiro 5 mg/160 mg.
ACE inhibitors and ARBs should therefore not be used concomitantly in patients with diabetic nephropathy (see section 4.4). 
Zato se pri bolnikih z diabetično nefropatijo zaviralcev ACE in antagonistov angiotenzinskih receptorjev ne sme uporabljati sočasno (glejte poglavje 4.4).
Not known (frequency cannot be estimated from the available data): Decrease in red blood cells, fever, sore throat or mouth sores due to infections; spontaneous bleeding or bruising; high level of potassium in the blood; abnormal liver test results; decreased renal functions and severely decreased renal functions; swelling mainly of the face and the throat; muscle pain; rash, purplish-red spots; fever; itching; allergic reaction; blistering skin (sign of a condition called dermatitis bullous). 
Pogostnost neznana (je ni mogoče oceniti iz razpoložljivih podatkov): zmanjšanje števila rdečih krvnih celic, zvišana telesna temperatura, vneto grlo in/ali žrelo ali razjede v ustih zaradi okužbe; krvavitev ali podplutba brez predhodne poškodbe; visoka koncentracija kalija v krvi; nenormalni izvidi jetrnih testov; zmanjšano delovanje ledvic in zelo zmanjšano delovanje ledvic; otekanje pretežno v obraz in žrelo oziroma grlo; bolečine v mišicah; izpuščaj, vijolično rdeče lise; zvišana telesna temperatura; srbenje; alergijska reakcija, pojavljanje mehurjev na koži (znak bolezni, ki jo imenujemo bulozni dermatitis).
Amlodipine stops calcium from moving into the blood vessel wall which stops the blood vessels from tightening. 
Amlodipin prepreči prehajanje kalcija v steno žil in tako prepreči zožitev žil.
Uncommon (may affect up to 1 in 100 people): Mood changes, anxiety, depression, sleeplessness, trembling, taste abnormalities, fainting, loss of pain sensation; visual disturbances, visual impairment, ringing in the ears; low blood pressure; sneezing/runny nose caused by inflammation of the lining of the nose (rhinitis); indigestion, vomiting (being sick); hair loss, increased sweating, itchy skin, skin discolouration; disorder in passing urine, increased need to urinate at night, increased number of times of passing urine; inability to obtain an erection, discomfort or enlargement of the breasts in men, pain, feeling unwell, muscle pain, muscle cramps; weight increase or decrease. 
Občasni (pojavijo se pri do 1 od 100 ljudi): spremembe razpoloženja, tesnobnost, depresija, nespečnost, tresenje, motnje okušanja, omedlevica, izguba občutka za bolečino; motnje vida, okvara vida, zvonjenje v ušesih; nizek krvni tlak; kihanje/izcedek iz nosu zaradi vnetja nosne sluznice (rinitis); slaba prebava, bruhanje; izpadanje las in dlak, čezmerno znojenje, srbeča koža, obarvanost kože; motnje uriniranja, pogosto uriniranje ponoči, zvečana pogostnost uriniranja; nezmožnost doseganja erekcije, nelagodje v dojkah ali čezmerna rast tkiva v dojkah pri moških, bolečine, slabo počutje, bolečine v mišicah, mišični krči; zvečanje ali zmanjšanje telesne mase.
Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx and/or tongue, has been reported in patients treated with valsartan. 
Pri bolnikih, ki so prejemali valsartan, so poročali o angioedemu, vključno z otekanjem grla in glasilk, ki povzroči obstrukcijo dihalnih poti in/ali otekanje obraza, ustnic, žrela in/ali jezika.
Therefore, blood pressure should be monitored and dose regulation considered both during and after concomitant medication particularly with strong CYP3A4 inducers (e.g. rifampicin, hypericum perforatum). 
Zato je med in po sočasnem zdravljenju, zlasti z močnimi induktorji CYP3A4 (npr. rifampicin, šentjanževka), treba spremljati krvni tlak in razmisliti o prilagoditvi odmerka.
Dafiro 10 mg/160 mg tablets are oval and light yellow with “NVR” on one side and “UIC” on the other side. 
Tablete zdravila Dafiro 10 mg/160 mg so ovalne in svetlorumene; na eni strani imajo oznako “NVR” in na drugi “UIC”.
Dafiro 5 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg alone. 
Zdravilo Dafiro 5 mg/160 mg lahko uporabite pri bolnikih, pri katerih krvni tlak ni ustrezno urejen samo s 5 mg amlodipina ali 160 mg valsartana.
Dafiro 5 mg/80 mg film-coated tablets Dafiro 5 mg/160 mg film-coated tablets Dafiro 10 mg/160 mg film-coated tablets 
Dafiro 5 mg/80 mg filmsko obložene tablete Dafiro 5 mg/160 mg filmsko obložene tablete Dafiro 10 mg/160 mg filmsko obložene tablete
Grapefruit and grapefruit juice should not be consumed by people who are taking Dafiro. 
Ljudje, ki jemljejo zdravilo Dafiro, ne smejo uživati grenivk in grenivkinega soka.
Hypromellose, substitution type 2910 (3 mPa.s) Titanium dioxide (E171) Iron oxide, yellow (E172) Macrogol 4000 
Obloga hipromeloza, substitucijski tip 2910 (3 mPa.s) titanov dioksid (E171) rumeni železov oksid (E172) makrogol 4000 smukec
Dafiro 5 mg/160 mg tablets are oval and dark yellow “NVR” on one side and “ECE” on the other side. 
Tablete zdravila Dafiro 5 mg/160 mg so ovalne in temnorumene; na eni strani imajo oznako “NVR” in na drugi “ECE”.
Aortic and mitral valve stenosis 
Stenoza aortne in mitralne zaklopke
These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient). 
Ti odmerki pri podganah (200 do 600 mg/kg/dan) so približno 6-krat in 18-krat večji od največjega priporočenega odmerka za ljudi na osnovi mg/m
The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous; magnesium stearate; hypromellose (substitution type 2910 (3 mPa.s)); macrogol 4000; talc, titanium dioxide (E171); iron oxide, yellow (E172). 
Druge sestavine zdravila so mikrokristalna celuloza, krospovidon (tipa A), brezvoden koloidni silicijev dioksid, magnezijev stearat, hipromeloza (substitucijski tip 2910 (3 mPa.s)), makrogol 4000, smukec, titanov dioksid (E171), rumeni železov oksid (E172).
In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. 
Po dajanju verapamila in intravenske infuzije dantrolena so pri živalih opazili ventrikularno fibrilacijo in srčnožilni kolaps s smrtnim izidom, v povezavi s hiperkaliemijo.
The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous; magnesium stearate; hypromellose (substitution type 2910 (3 mPa.s)); macrogol 4000; talc, titanium dioxide (E171); iron oxide, yellow (E172), iron oxide, red (E172). 
Druge sestavine zdravila so mikrokristalna celuloza, krospovidon (tipa A), brezvoden koloidni silicijev dioksid, magnezijev stearat, hipromeloza (substitucijski tip 2910 (3 mPa.s)), makrogol 4000, smukec, titanov dioksid (E171), rumeni železov oksid (E172), rdeči železov oksid (E172).
Common (may affect up to 1 in 10 people): Dizziness, sleepiness; palpitations (awareness of your heart beat); flushing, ankle swelling (oedema); abdominal pain, feeling sick (nausea). 
Pogosti (pojavijo se pri do 1 od 10 ljudi): omotica, zaspanost; palpitacije (zavedanje bitja vašega srca); vročinski oblivi, otekanje gležnjev (edem); bolečine v trebuhu, slabost s siljenjem na bruhanje (navzea).
No dosage adjustment is required for patients with mild to moderate renal impairment. 
DafiroBolnikom z blago do zmerno okvaro ledvic odmerka ni treba prilagoditi.
In an embryo-foetal development study in the rat, increased incidences of dilated ureters, malformed sternebrae, and unossified forepaw phalanges were noticed at exposures of about 12 (valsartan) and 10 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine. 
V študiji embriofetalnega razvoja pri podganah so pri izpostavljenosti, ki je bila za valsartan okrog 12-krat in za amlodipin okrog 10-krat večja kot ob kliničnih odmerkih 160 mg valsartana in 10 mg amlodipina, ugotovili večjo incidenco razširjenih ureterjev, malformirane sternebre in nezakostenele falange sprednjih tac.
The addition of amlodipine 10 mg and 5 mg produced an additional reduction in systolic/diastolic blood pressure of 6.0/4.8 mmHg and 3.9/2.9 mmHg, respectively, compared to patients who remained on valsartan 160 mg only. 
V primerjavi z bolniki, ki so ostali samo na 160 mg valsartana, je dodatek 10 mg amlodipina dodatno znižal sistolični krvni tlak za 6,0 mm Hg in diastoličnega za 4,8 mm Hg, 5 mg amlodipina pa sistolični krvni tlak za 3,9 mm Hg in diastoličnega za 2,9 mm Hg.
A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation of blood pressure (trough sitting diastolic blood pressure <90 mmHg at the end of the trial) in patients not adequately controlled on amlodipine 10 mg in 78% of patients treated with amlodipine/valsartan 10 mg/160 mg, compared to 67% of patients remaining on amlodipine 10 mg. 
Pokazalo je, da se je krvni tlak normaliziral (najnižji diastolični krvni tlak sede <90 mm Hg na koncu preskušanja) pri 78 % bolnikov, ki so dobivali amlodipin/valsartan 10 mg/160 mg, in pri 67 % bolnikov, ki so ostali na 10 mg amlodipina.
No information is available regarding the use of Dafiro during breast-feeding, therefore Dafiro is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant. 
Za uporabo med dojenjem je bolje izbrati drugo zdravilo z dokazanim varnostnim profilom, še posebno če gre za dojenje novorojenčka ali nedonošenčka.
Active-controlled trials in patients who were non-responders to monotherapy A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation of blood pressure (trough sitting diastolic blood pressure <90 mmHg at the end of the trial) in patients not adequately controlled on valsartan 160 mg in 75% of patients treated with amlodipine/valsartan 10 mg/160 mg and 62% of patients treated with amlodipine/valsartan 5 mg/160 mg, compared to 53% of patients remaining on valsartan 160 mg. 
Pokazalo se je, da se je krvni tlak normaliziral (najnižji diastolični krvni tlak sede <90 mm Hg na koncu preskušanja) pri 75 % bolnikov, ki so dobivali amlodipin/valsartan 10 mg/160 mg, pri 62 % bolnikov, ki so dobivali amlodipin/valsartan 5 mg/160 mg in pri 53 % bolnikov, ki so ostali na 160 mg valsartana.
Uncommon (may affect up to 1 in 100 people): Dizziness; nausea and abdominal pain; dry mouth; drowsiness, tingling or numbness of the hands or feet; vertigo; fast heart beat including palpitations; dizziness on standing up; cough; diarrhoea; constipation; skin rash, redness of the skin; joint swelling, back pain; pain in joints. 
Občasni (pojavijo se pri do 1 od 100 ljudi): omotica; slabost v želodcu in bolečine v trebuhu; suhost ust; zaspanost, mravljinčenje ali omrtvelost dlani in stopal; vrtoglavica; hitro bitje srca, vključno s palpitacijami; omotičnost stoje; kašelj; driska; zaprtje; osip, pordelost kože; oteklost sklepov, bolečine v hrbtu; bolečine v sklepih.
Dafiro 5 mg/80 mg film-coated tablets 
Dafiro 5 mg/80 mg filmsko obložene tablete
A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, 
Za obnovitev žilnega tonusa in krvnega tlaka lahko koristi vazokonstriktor, če za njegovo uporabo ni kontraindikacij.
Dafiro 5 mg/80 mg film-coated tablets Dafiro 5 mg/160 mg film-coated tablets Dafiro 10 mg/160 mg film-coated tablets amlodipine/valsartan 
Dafiro 5 mg/80 mg filmsko obložene tablete Dafiro 5 mg/160 mg filmsko obložene tablete Dafiro 10 mg/160 mg filmsko obložene tablete amlodipin/valsartan
if you have experienced swelling, particularly of the face and throat, while taking other medicines (including angiotensin converting enzyme inhibitors). 
če je v času jemanja drugih zdravil (kar vključuje tudi zaviralce angiotenzinske konvertaze) pri vas prišlo do otekanja, zlasti v obraz in grlo oziroma žrelo.
Monitoring of potassium levels and creatinine is advised in moderate renal impairment. 
Pri bolnikih z zmerno okvaro ledvic je priporočljivo kontrolirati koncentracije kalija in kreatinina.
Dafiro 10 mg/160 mg film-coated tablets 
Dafiro 10 mg/160 mg filmsko obložene tablete
Amlodipine dosage recommendations have not been established in patients with mild to moderate hepatic impairment. 
Pri bolnikih z blago do zmerno okvaro jeter priporočljivega odmerjanja amlodipina niso ugotavljali.
Each tablet contains 5 mg amlodipine and 80 mg valsartan. 
Ena tableta vsebuje 5 mg amlodipina in 80 mg valsartana.
Light yellow, oval film-coated tablet, imprinted with “NVR” on one side and “UIC” on the other side. 
Svetlorumene, ovalne filmsko obložene tablete, ki imajo na eni strani oznako “NVR” in na drugi “UIC”.
EU/1/06/371/035 280 film-coated tablets (4x70) EU/1/06/371/038 280 film-coated tablets (20x14) 
EU/1/06/371/035 280 filmsko obloženih tablet (4x70) EU/1/06/371/038 280 filmsko obloženih tablet (20x14)
How to store Dafiro 
Shranjevanje zdravila Dafiro
An increased incidence and severity of renal tubular basophilia/hyalinisation, dilation and casts, as well as interstitial lymphocyte inflammation and arteriolar medial hypertrophy were found at an exposure of 8-13 (valsartan) and 7-8 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine. 
Pri izpostavljenosti, ki je bila za valsartan od 8- do 13-krat večja in za amlodipin od 7- do 8-krat večja kot ob kliničnih odmerkih 160 mg valsartana in 10 mg amlodipina, so ugotovili večjo pojavnostjo in izrazitost bazofilije/hialinizacije, dilatacije in cilindrov ledvičnih tubulov ter intersticijskega limfocitnega vnetja in hipertrofije arteriolarne medije.
EU/1/06/371/036 280 film-coated tablets (4x70) EU/1/06/371/039 280 film-coated tablets (20x14) 
EU/1/06/371/036 280 filmsko obloženih tablet (4x70) EU/1/06/371/039 280 filmsko obloženih tablet (20x14)
EU/1/06/371/017 EU/1/06/371/018 EU/1/06/371/019 EU/1/06/371/020 EU/1/06/371/021 EU/1/06/371/022 EU/1/06/371/023 EU/1/06/371/024 EU/1/06/371/031 EU/1/06/371/032 EU/1/06/371/033 EU/1/06/371/036 EU/1/06/371/039 
EU/1/06/371/017 EU/1/06/371/018 EU/1/06/371/019 EU/1/06/371/020 EU/1/06/371/021 EU/1/06/371/022 EU/1/06/371/023 EU/1/06/371/024
Dafiro 10 mg/160 mg film-coated tablets amlodipine/valsartan 
Dafiro 10 mg/160 mg filmsko obložene tablete amlodipin/valsartan
EU/1/06/371/034 280 film-coated tablets (4x70) EU/1/06/371/037 280 film-coated tablets (20x14) 
EU/1/06/371/034 280 filmsko obloženih tablet (4x70) EU/1/06/371/037 280 filmsko obloženih tablet (20x14)
Dafiro 5 mg/160 mg film-coated tablets 
Dafiro 5 mg/160 mg filmsko obložene tablete
Uncommon Insomnia, mood changes (including anxiety), depression, tremor, dysgeusia, syncope, hypoesthesia, visual disturbance (including diplopia), tinnitus, hypotension, dyspnoea, rhinitis, vomiting, dyspepsia, alopecia, purpura, skin discolouration, hyperhidrosis, pruritus, exanthema, myalgia, muscle cramps, pain, micturition disorder, increased urinary frequency, impotence, gynaecomastia, chest pain, malaise, weight increase, weight decrease. 
Amlodipin pogosti somnolenca, omotica, palpitacije, bolečine v trebuhu, navzea, otekanje gležnjev nespečnost, spremembe razpoloženja (vključno z anksioznostjo), depresija, tremor, motnje v zaznavanju okusa, sinkopa, hipestezija, motnje vida (vključno z diplopijo), tinitus, hipotenzija, dispneja, rinitis, bruhanje, dispepsija, alopecija, purpura, obarvanje kože, hiperhidroza, srbenje, eksantem, mialgija, mišični krči, bolečine, motnje uriniranja, zvečana pogostnost uriniranja, impotenca, ginekomastija, bolečine v prsih, slabo počutje, zvečanje ali zmanjšanje telesne mase redki zmedenost zelo redki levkopenija, trombocitopenija, alergijske reakcije, hiperglikemija, hipertonija, periferna nevropatija, miokardni infarkt, aritmija (vključno z bradikardijo, ventrikularno tahikardijo in atrijsko fibrilacijo), vaskulitis, pankreatitis, gastritis, hiperplazija dlesni, hepatitis, zlatenica, zvišanje ravni jetrnih encimov*, angioedem, multiformni eritem, urtikarija, eksfoliativni dermatitis, Stevens-Johnsonov sindrom, Quinckejev edem, fotosenzitivnost pogostnost neznana toksična epidermalna nekroliza * o tem so najpogosteje poročali v povezavi s holestazo Izjemoma so poročali o primerih ekstrapiramidnega sindroma.
Each tablet contains 10 mg amlodipine and 160 mg valsartan. 
Ena tableta vsebuje 10 mg amlodipina in 160 mg valsartana.
Hypromellose, substitution type 2910 (3 mPa.s) Titanium dioxide (E171) Iron oxide, yellow (E172) Iron oxide, red (E172) 
Obloga hipromeloza, substitucijski tip 2910 (3 mPa.s) titanov dioksid (E171) rumeni železov oksid (E172) rdeči železov oksid (E172) makrogol 4000 smukec
What Dafiro looks like and contents of the pack Dafiro 5 mg/80 mg tablets are round and dark yellow with “NVR” on one side and “NV” on the other side. 
Tablete zdravila Dafiro 5 mg/80 mg so okrogle in temnorumene; na eni strani imajo oznako “NVR” in na drugi “NV”.
Dark yellow, round film-coated tablet with bevelled edges, imprinted with “NVR” on one side and “NV” on the other side. 
Temnorumene, okrogle filmsko obložene tablete s poševnimi robovi, ki imajo na eni strani oznako “NVR” in na drugi “NV”.
The addition of valsartan 160 mg produced an additional reduction in systolic/diastolic blood pressure of 2.9/2.1 mmHg compared to patients who remained on amlodipine 10 mg only. 
V primerjavi z bolniki, ki so ostali samo na 10 mg amlodipina, je dodatek 160 mg valsartana dodatno znižal sistolični krvni tlak za 2,9 mm Hg in diastoličnega za 2,1 mm Hg.
Each tablet contains 5 mg amlodipine and 160 mg valsartan. 
Ena tableta vsebuje 5 mg amlodipina in 160 mg valsartana.
ACE inhibitors and ARBs should not be used concomitantly in patients with diabetic nephropathy. 
Pri bolnikih z diabetično nefropatijo se zaviralcev ACE in antagonistov angiotenzinskih receptorjev ne sme uporabljati sočasno.
Dafiro 5 mg/80 mg film-coated tablets amlodipine/valsartan 
Dafiro 5 mg/80 mg filmsko obložene tablete amlodipin/valsartan
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, including valsartan.. 
Med sočasno uporabo litija in zaviralcev angiotenzinske konvertaze ali antagonistov angiotenzinskih receptorjev tipa II, vključno z valsartanom, so poročali o reverzibilnem povečanju koncentracije litija v serumu in povečanju njegovih toksičnih učinkov.
EU/1/06/371/009 EU/1/06/371/010 EU/1/06/371/011 EU/1/06/371/012 EU/1/06/371/013 EU/1/06/371/014 EU/1/06/371/015 EU/1/06/371/016 EU/1/06/371/028 EU/1/06/371/029 EU/1/06/371/030 EU/1/06/371/035 EU/1/06/371/038 
EU/1/06/371/009 EU/1/06/371/010 EU/1/06/371/011 EU/1/06/371/012 EU/1/06/371/013 EU/1/06/371/014 EU/1/06/371/015 EU/1/06/371/016
Dark yellow, oval film-coated tablet, imprinted with “NVR” on one side and “ECE” on the other side. 
Temnorumene, ovalne filmsko obložene tablete, ki imajo na eni strani oznako “NVR” in na drugi “ECE”.
Dafiro 5 mg/160 mg film-coated tablets amlodipine/valsartan 
Dafiro 5 mg/160 mg filmsko obložene tablete amlodipin/valsartan
Uncommon Very rare Uncommon 
Bolezni imunskega sistema preobčutljivost redki zelo redki pogostnost neznana
EU/1/06/371/017 7 film-coated tablets EU/1/06/371/018 14 film-coated tablets EU/1/06/371/019 28 film-coated tablets EU/1/06/371/020 30 film-coated tablets EU/1/06/371/021 56 film-coated tablets EU/1/06/371/022 90 film-coated tablets EU/1/06/371/023 98 film-coated tablets EU/1/06/371/024 280 film-coated tablets EU/1/06/371/031 56x1 film-coated tablet (unit dose) EU/1/06/371/032 98x1 film-coated tablet (unit dose) EU/1/06/371/033 280x1 film-coated tablet (unit dose) 
EU/1/06/371/017 7 filmsko obloženih tablet EU/1/06/371/018 14 filmsko obloženih tablet EU/1/06/371/019 28 filmsko obloženih tablet EU/1/06/371/020 30 filmsko obloženih tablet EU/1/06/371/021 56 filmsko obloženih tablet EU/1/06/371/022 90 filmsko obloženih tablet EU/1/06/371/023 98 filmsko obloženih tablet EU/1/06/371/024 280 filmsko obloženih tablet EU/1/06/371/031 56x1 filmsko obložena tableta (za enkratni odmerek) EU/1/06/371/032 98x1 filmsko obložena tableta (za enkratni odmerek) EU/1/06/371/033 280x1 filmsko obložena tableta (za enkratni odmerek)
EU/1/06/371/009 7 film-coated tablets EU/1/06/371/010 14 film-coated tablets EU/1/06/371/011 28 film-coated tablets EU/1/06/371/012 30 film-coated tablets EU/1/06/371/013 56 film-coated tablets EU/1/06/371/014 90 film-coated tablets EU/1/06/371/015 98 film-coated tablets EU/1/06/371/016 280 film-coated tablets EU/1/06/371/028 56x1 film-coated tablet (unit dose) EU/1/06/371/029 98x1 film-coated tablet (unit dose) EU/1/06/371/030 280x1 film-coated tablet (unit dose) 
EU/1/06/371/009 7 filmsko obloženih tablet EU/1/06/371/010 14 filmsko obloženih tablet EU/1/06/371/011 28 filmsko obloženih tablet EU/1/06/371/012 30 filmsko obloženih tablet EU/1/06/371/013 56 filmsko obloženih tablet EU/1/06/371/014 90 filmsko obloženih tablet EU/1/06/371/015 98 filmsko obloženih tablet EU/1/06/371/016 280 filmsko obloženih tablet EU/1/06/371/028 56x1 filmsko obložena tableta (za enkratni odmerek) EU/1/06/371/029 98x1 filmsko obložena tableta (za enkratni odmerek) EU/1/06/371/030 280x1 filmsko obložena tableta (za enkratni odmerek)
EU/1/06/371/001 7 film-coated tablets EU/1/06/371/002 14 film-coated tablets EU/1/06/371/003 28 film-coated tablets EU/1/06/371/004 30 film-coated tablets EU/1/06/371/005 56 film-coated tablets EU/1/06/371/006 90 film-coated tablets EU/1/06/371/007 98 film-coated tablets EU/1/06/371/008 280 film-coated tablets EU/1/06/371/025 56x1 film-coated tablet (unit dose) EU/1/06/371/026 98x1 film-coated tablet (unit dose) EU/1/06/371/027 280x1 film-coated tablet (unit dose) 
EU/1/06/371/001 7 filmsko obloženih tablet EU/1/06/371/002 14 filmsko obloženih tablet EU/1/06/371/003 28 filmsko obloženih tablet EU/1/06/371/004 30 filmsko obloženih tablet EU/1/06/371/005 56 filmsko obloženih tablet EU/1/06/371/006 90 filmsko obloženih tablet EU/1/06/371/007 98 filmsko obloženih tablet EU/1/06/371/008 280 filmsko obloženih tablet EU/1/06/371/025 56x1 filmsko obložena tableta (za enkratni odmerek) EU/1/06/371/026 98x1 filmsko obložena tableta (za enkratni odmerek) EU/1/06/371/027 280x1 filmsko obložena tableta (za enkratni odmerek)
Given their similar pharmacodynamic properties, these results are also relevant for other ACE inhibitors and ARBs. 
Ti izsledki so pomembni tudi za druge zaviralce ACE in antagoniste angiotenzinskih receptorjev, ker so njihove farmakodinamične lastnosti podobne.
Each tablet contains 10 mg amlodipine (as amlodipine besylate) and 160 mg valsartan. 
Ena tableta vsebuje 10 mg amlodipina (v obliki amlodipinijevega besilata) in 160 mg valsartana.
Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate) and 80 mg of valsartan. 
Ena filmsko obložena tableta vsebuje 5 mg amlodipina (v obliki amlodipinijevega besilata) in 80 mg valsartana.